IGC Pharma, Inc. is a clinical-stage company, which is engaged in developing treatments for Alzheimer’s disease. The Company’s flagship drug, IGC-AD1, is an investigational drug tackles agitation, a major burden for patients and caregivers by addressing neuroinflammation. The Company operates through two segments: Life Sciences Segment and Infrastructure Segment. Its TGR-63 has demonstrated its potential to disrupt the progression of Alzheimer’s by targeting Aβ plaques, a key disease hallmark. The Company’s IGC-1C represents a potential breakthrough by targeting tau protein and neurofibrillary tangles, aiming to modify the disease course. Its IGC-M3 focuses on early intervention by inhibiting Aβ plaque formation, potentially slowing cognitive decline. Its LMP is designed to target multiple hallmarks of Alzheimer’s disease, including Aβ plaques and neurofibrillary tangles for a comprehensive therapeutic effect. It seeks to leverage artificial intelligence (AI) for Alzheimer's research.
Growing
The company is in a growing phase, with the latest annual income totaling USD 869.00K.
Overvalued
The company’s latest PE is 43.12, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 22.48M shares, increasing 11.30% quarter-over-quarter.
Held by Ken Fisher
Star Investor Ken Fisher holds 39.34K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.28.